Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders.
CONCLUSIONS: The current body of evidence supports the use of select DOACs for the treatment of CAT. In contrast, DOAC use in patients with APS and hereditary thrombophilia should be avoided at this time.
PMID: 33100017 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Valanejad SM, Davis KA Tags: Ann Pharmacother Source Type: research
More News: Antiphospholipid Syndrome | Bleeding | Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Hughes Syndrome | Oral Cancer | Pradaxa | Study | Thrombosis